Telmisartan

Long-half-life ARB (~24 hr, longest of the class) that also weakly agonizes PPARγ — making it the only ARB with a real metabolic angle (mild insulin sensitization, modest lipid improvement) on top of standard BP control. FDA-approved for hypertension and CV risk reduction. Bodybuilding/AAS communities have made it the default ARB for on-cycle BP because the metabolic profile complements an already-stressed cardiometabolic system. For Dylan: NOT-RELEVANT now (no HTN, no AAS, no metabolic indication). Becomes STRONG-CANDIDATE on first AAS cycle, on sustained BP >130/85, or if bloodwork reveals insulin/lipid drift.

The renin-angiotensin system (RAS) in plain English:

1. Kidneys sense low perfusion → release renin.
2. Renin cleaves angiotensinogen (from liver) into angiotensin I.
3. ACE (angiotensin-converting enzyme) cleaves angiotensin I into angiotensin II.
4. Angiotensin II binds AT1 receptor → vasoconstriction, aldosterone release (Na+/water retention), sympathetic activation, vascular remodeling, fibrosis.

Telmisartan blocks step 4 selectively at AT1. The vasoconstrictive, sodium-retaining, fibrotic arm of RAS goes quiet; the AT2 arm (which is generally counter-regulatory and arguably protective) is left untouched. Net effect: BP drops ~8-15 mmHg systolic in hypertensives, less in normotensives; aldosterone drops; left ventricular hypertrophy and arterial stiffness slowly reverse over months.

What makes telmisartan different from other ARBs:

• Half-life ~24 hours — the longest of any ARB (vs losartan ~6-9 hr, valsartan ~6 hr, irbesartan ~11-15 hr, olmesartan ~13 hr). Once-daily dosing gives true 24-hr coverage including the early-morning BP surge that drives a lot of CV events.
• Partial PPARγ agonist — this is the differentiator. Telmisartan binds PPARγ with affinity ~25-30% of pioglitazone (a full thiazolidinedione PPARγ agonist used for type 2 diabetes). At standard 40-80 mg doses, this is enough to:
  • Modestly improve insulin sensitivity (small but real HOMA-IR drops in trials)
  • Mildly raise HDL, lower triglycerides
  • Reduce visceral adiposity slightly in some trials
  • Without the weight gain, edema, or CHF risk that comes with full PPARγ agonism
• Highly lipophilic — best CNS penetration of any ARB; matters for central RAS effects (autonomic tone, possibly cognition in the elderly).
• Hepatic clearance, not renal — useful in mild-moderate CKD because dose adjustment isn't required.

For practical purposes: telmisartan is "an ARB that also nudges your metabolism in the right direction." Whether the PPARγ effect is clinically meaningful in normometabolic patients is debated, but it's why bodybuilders and AAS users specifically reach for telmisartan over losartan or valsartan.